Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Smita S. Chandran(Memorial Sloan Kettering Cancer Center), Christopher A. Klebanoff(Memorial Sloan Kettering Cancer Center)
Cited by 126
Related Papers
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy
|JCI Insight|2017|221
Immunogenicity of a public neoantigen derived from mutated <i>PIK3CA</i>
|bioRxiv (Cold Spring Harbor Laboratory)|2021|3